MENUNews Archive
Date: 04/01/2025
Four Rogel Cancer Center members earned election to the American Association for the Advancement of Science in 2024. The AAAS is the world’s largest general scientific society. Fellows are elected for their “efforts on behalf of the advancement of science, or its applications, are scientifically or socially distinguished.”
Date: 03/31/2025
Rogel Cancer Center and University of Michigan researchers will be represented in more than 60 presentations and poster sessions. Check the list below to support your colleagues. All times listed are Central Time.
Date: 03/25/2025
Cancer antigen-encoding RNA vaccines, or circRNA, is a targeted technology that improves existing immunotherapy and vaccine approaches
Date: 03/25/2025
A revolutionary new therapy, called histotripsy uses soundwaves to destroy liver tumors and was approved for clinical use by the FDA in 2023. A recent study in the journal Cancers demonstrates how histotripsy could stimulate the immune system to destroy a cancer through the release of tumor antigens.
Date: 03/25/2025
Avapritinib, an FDA-approved drug used to treat other types of cancer, also decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma
Date: 03/25/2025
The standard treatment for most cancers is chemotherapy and surgery. However, for tumors in the brain and spinal cord treatments can be challenging, because they are often difficult to access due to their location and can be very aggressive. Unfortunately, there are limited therapy options for patients with inoperable tumors. The development of chimeric antigen receptor T cells is a promising new type of cancer therapy. CAR T treatment helps the patient’s own body and immune system to target the tumor.
Date: 03/14/2025
The Thyroid and Thyroid Cancer Research team, or ThyCARE, at the Rogel Cancer Center received the inaugural Endocrine Care Innovation Award from the American Association of Endocrinology.
Date: 03/12/2025
Andrea Franson, M.D., M.S., received an $800,000 “A” Award grant from Alex’s Lemonade Stand Foundation for Childhood Cancer to translate an approach developed at Rogel Cancer Center into a phase 1 clinical trial for children with high-grade glioma.
Date: 01/31/2025
Researchers from the University of Michigan Rogel Cancer Center and BenevolentAI have identified a promising new therapeutic approach for platinum-resistant ovarian cancer.
Date: 12/31/2024
Researchers from the University of Michigan have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer patients. As tumors develop, they shed cells into the bloodstream. Although these circulating tumor cells are vastly outnumbered by millions of other blood cells, detecting them early can potentially improve treatment outcomes.